NCT04673617 2025-06-11AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaArtiva Biotherapeutics, Inc.Phase 1/2 Active not recruiting45 enrolled
NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled
NCT03778619 2020-07-28MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginGC Cell CorporationPhase 1/2 Unknown9 enrolled
NCT00100737 2006-02-06Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)Chiron CorporationPhase 2 Terminated300 enrolled